BackHeat Biologics Overview

Heat Biologics Receivables

Latest receivables for HTBX: $180B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$179.89B

Peer trimmed avg / median

Loading

Heat Biologics Receivables History

Loading

Heat Biologics vs. peers: Receivables Comparison

Loading

Heat Biologics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Heat Biologics (HTBX) FAQ

As of the most recent data (September 2025), HTBX shows a receivables of $180B. Scroll down for historical charts and peer comparison views.

Tracking HTBX's receivables over time shows whether Heat Biologics is scaling, shrinking, or reshaping that part of the business. The current reading is $180B Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Heat Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $180B) with ownership activity and broader fundamentals.

Heat Biologics's receivables is $180B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.